MWNA
PAND

Marshall Wace North America’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Marshall Wace North America’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-27,569
Closed -$409K – 1915
2020
Q4 		$409K Hold
27,569
– – ﹤0.01% 1122
2020
Q3 		$316K Buy
+27,569
New +$471K ﹤0.01% 1061

Other funds holding PAND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's PAND Position: Q1 2021 in Review

Marshall Wace North America sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q1 2021, closing a stake of 27,569 shares — an estimated $409K sold.

Marshall Wace North America first reported a position in PAND in Q3 2020 and held it in 2 quarters. The position peaked at $409K in Q4 2020. 75 funds tracked by Wall St. Rank hold PAND as of Q1 2021.

  • Marshall Wace North America reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 27,569 Pandion Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $409K.
  • Marshall Wace North America first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Marshall Wace North America's Pandion Therapeutics Inc. Common Stock position peaked at $409K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.